雅虎香港 搜尋

  1. JobMarket 相關

    廣告
  2. 35年專業仲介海外或現成印傭、泰傭,孟加拉傭,港式家政及粵語訓練,信譽良好. 35年經驗,精選純樸、健康的菲傭、印傭、斯里蘭卡傭大量在港完約工人,開工快

搜尋結果

  1. 2024年2月22日 · SEEK在收購亞洲領先的網上求職招聘平台Jobsdb和Jobstreet十年後,近日亦完成與Jobsdb及Jobstreet的跨系統整合。. 新平台由母公司SEEK領先的人工智能技術驅動,一方面協助僱主挑選更合適的人才,另一方面為求職者提供更全面、橫跨八個亞太區市場的工作機會 ...

  2. 2024年1月30日 · HONG KONG, Jan. 30, 2024 /PRNewswire/ — Hudson, a prominent recruitment agency in Hong Kong, is delighted to unveil its insights on the job market outlook for the year 2024.

  3. 2023年12月12日 · HONG KONG SAR – Media OutReach Newswire – 12 December 2023 – The job market in Hong Kong has faced significant challenges in 2023, amidst concerns of a global recession. However, there are signs of potential marginal improvements in 2024 compared to 2023, indicating a slow recovery.

  4. 2024年6月17日 · Bill Lee, Managing Director, Hong Kong, Jobsdb by SEEK, said, “As the interconnection and interchange of talents between Hong Kong and Mainland China is poised to be a growing trend, Jobsdb is delighted to enter into an exclusive partnership with Zhaopin.

  5. 4 天前 · SINGAPORE, June 20, 2024 /PRNewswire/ — In the ever-evolving landscape of the workforce market, Bossjob emerges as a beacon for global job seekers and employers… SINGAPORE, June 20, 2024 /PRNewswire/ — In the ever-evolving landscape of the workforce market, Bossjob emerges as a beacon for global job seekers and employers, offering an AI-powered recruitment platform that transcends ...

  6. 2023年6月8日 · HONG KONG, June 8, 2023 /PRNewswire/ — JobsDB, the leading employment marketplace by SEEK, released its latest “Job Seeker Salary Report 2023”, marking a three-year streak of pay rises. Average pay rise in 2023 recorded 4.1%, the highest increase in the past four years, maintaining its trend of outpacing inflation.

  7. 23 小時前 · MAINZ, Germany and SHANGHAI, China, June 24, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today… Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with ...

  1. 其他人也搜尋了